If you have been reading about Phase 3 trial and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Last reviewed on 2025-08-13. Where a claim depends on a specific study, the study is described rather than over-claimed.
Assays for these markers differ in calibration and antibody specificity, so results from different platforms are not always interchangeable. Reported values can shift when a laboratory changes method, even without any biological change. Studies that span long periods or multiple sites often need cross-validation of assays. This methodological variability is a recognized limitation when comparing findings across published reports, and it remains a topic of ongoing standardization work.
Measuring the effect of a growth hormone-releasing hormone analogue requires markers that reflect pituitary output rather than the peptide itself. The two most frequently used are growth hormone and insulin-like growth factor 1. Growth hormone fluctuates sharply across the day and responds to sleep, stress, and meals, so isolated readings can be difficult to interpret. Insulin-like growth factor 1 changes more slowly and is often treated as the more stable integrated marker of axis activity.
Because growth hormone is released in pulses, single measurements can misrepresent overall secretion. Investigators sometimes use repeated sampling or overnight profiles to capture the pattern rather than a single value. Provocative testing, in which a stimulus is given and the response is tracked over time, offers another way to characterize the axis. Each approach carries trade-offs between sensitivity, burden on the participant, and the influence of non-target variables.
Binding of tesamorelin to GHRH receptors on pituitary somatotroph cells triggers cyclic AMP signaling and the release of growth hormone into circulation. Because the peptide acts upstream of the growth hormone axis, its effects are partly mediated by hepatic insulin-like growth factor 1 (IGF-1) production. The pulsatile character of endogenous growth hormone secretion is preserved rather than replaced. Whether amplified signaling produces effects beyond those of native GHRH remains an area of ongoing investigation.
A documented effect of tesamorelin is a reduction in visceral adipose tissue in some study populations. Researchers have reported decreases in trunk fat measured by computed tomography alongside changes in lipid markers. The mechanism is thought to involve growth hormone-mediated lipolysis, though the precise contribution of direct versus indirect pathways is not fully resolved. Studies have generally examined defined groups over finite periods, so long-term outcomes are less well characterized. Findings have not been uniform across all trials.
Tesamorelin is a synthetic peptide analog of growth hormone-releasing hormone (GHRH). Its sequence corresponds to the 44-amino-acid form of human GHRH with a trans-3-hexenoyl group attached to the N-terminal tyrosine. This modification slows enzymatic cleavage and extends the peptide's activity relative to the native hormone. The compound is produced by solid-phase peptide synthesis and supplied as a lyophilized powder. Researchers classify it as a GHRH receptor agonist. Its structure places it in the same family as other growth hormone secretagogues that act on the pituitary.
| Property | Value | Notes |
|---|---|---|
| Primary marker | Insulin-like growth factor 1 | Slow-changing integrated indicator of axis activity |
| Secondary marker | Growth hormone | Pulsatile; requires repeated or timed sampling |
| Typical analytical method | Immunoassay | Antibody-based quantification in serum |
| Common sample matrix | Serum | Collected under standardized conditions |
| Key interpretation factor | Age-stratified reference ranges | Baseline marker concentrations shift with age |
Tesamorelin binds to growth hormone-releasing hormone receptors on somatotroph cells in the anterior pituitary. Receptor activation increases intracellular cyclic AMP and promotes synthesis and secretion of growth hormone. Because the peptide mimics endogenous GHRH, it amplifies the normal pulsatile release of growth hormone rather than providing exogenous growth hormone directly. This upstream action distinguishes tesamorelin from recombinant growth hormone preparations and from growth hormone secretagogues that act at different receptors.
Stimulated growth hormone release leads to hepatic production of insulin-like growth factor 1, a key mediator of many growth hormone effects. In clinical studies, tesamorelin increased IGF-1 levels in a dose-dependent manner, although the response varies among individuals. The drug's effect on visceral fat is thought to involve growth hormone-mediated lipolysis and altered adipocyte metabolism. Muscle mass and lean body mass have also been assessed as secondary outcomes, but changes are generally smaller and less consistent than fat reductions.
Pharmacodynamic studies show that tesamorelin reduces visceral adipose tissue more than subcutaneous adipose tissue in the studied population. This selectivity may relate to differences in blood flow and hormone sensitivity between fat depots. Effects on glucose metabolism and insulin sensitivity have been investigated, with some trials reporting modest changes and others showing stability. The precise relationship between growth hormone exposure, IGF-1 levels, and visceral fat loss remains an active area of analysis.
Tesamorelin is a synthetic peptide that belongs to the growth hormone-releasing hormone family and contains the same forty-four amino acid sequence as endogenous GHRH, extended at the amino terminus by a trans-3-hexenoyl group. That small fatty acid modification protects the peptide from rapid cleavage by dipeptidyl peptidase-4, the enzyme that shortens the half-life of native GHRH to only a few minutes. Chemically the compound is produced by solid-phase peptide synthesis, purified by chromatography, and supplied as a sterile lyophilized powder for reconstitution.
Regulatory approval in the United States came in 2010, when the Food and Drug Administration cleared the peptide for the reduction of excess abdominal fat in adults with HIV infection and associated lipodystrophy. The decision rested mainly on two randomized phase 3 trials that enrolled roughly eight hundred patients and ran for twenty-six weeks. Participants receiving active drug showed substantially greater declines in visceral adipose tissue than those receiving placebo, while total body weight changed comparatively little. A reformulated presentation was later approved, and the product has remained a niche therapy rather than a general weight-loss agent.
Tesamorelin occupies a narrow position among agents that act on the growth hormone axis. Unlike growth hormone itself, which is given as replacement, it stimulates the pituitary to release the hormone in pulses, so the downstream increase in insulin-like growth factor 1 depends on intact somatotroph function. Other peptides in the same family include shorter GHRH fragments and synthetic secretagogues with different stability profiles. Several points remain unresolved, including whether the reduction in visceral fat translates into fewer cardiovascular events, what happens to metabolic markers after long-term use, and how the drug compares with lifestyle or surgical approaches.
== Biography == Robert Brownlee was born October 21, 1942, in South Dakota. He founded Brownlee Labs in the 1970s, in the San Francisco Bay area, a manufacturer of columns and pumps for high-performance liquid chromatography systems. Bob Brownlee took the initiative "along with Tom Jupille, Steve Bakalyar, Nelson Cooke, Jerry Higgins and Ron Majors" to form the Bay Area Chromatography Colloquium. Bob Stevenson is quoted as saying in his Nine Lives of the California Separation Science Society that Brownlee Labs was "certainly one of the globe's leaders in HPLC column technology." In the 1980s, when Robert Brownlee was diagnosed with AIDS-related complex, he sold his company to Applied Biosystems of Foster City, California, in 1984. (Applied later merged with Perkin-Elmer). Sometime later, he began a new company, which was viewed by Applied as a competitor. A lawsuit was instituted and later settled (Brownlee v. Applied Biosystems, Inc., 1989-1 Trade Cas. (CCH) ¶ 68, (N.D. Cal. 1989) 8,14). In 1990, he was interviewed for an article in The Scientist about Applied Biosystems. "If you produce the first product for these virgins [scientists without such equipment], you have a big value added, and you can charge a big price for your product," Brownlee says. "That's the reason Applied Biosystems did so well." He also formed the Robert Brownlee Foundation, a private family foundation which supports, with grants, K–12 science.
=== Human use === Nitrofurazone was previously available as a prescription in the U.S., and was indicated as a topical solution, topical cream, or topical ointment for the treatment of bacterial skin infections, wounds, burns, and ulcers. It was also used as a prophylactic measure to prevent infection that could potentially result in skin graft rejection. Nitrofurazone is still very popular as a topical solution for the treatment of tonsillitis in Russia.
=== LGR4 === LGR4 binds R-spondins to activate the Wnt signaling pathway. Wnt signaling regulates bone mass and osteoblast differentiation and is important for the development of bone, heart, and muscle. An LGR4 nonsense mutation in a healthy population has been linked to low bone mass density and symptoms of osteoporosis. LGR4 mutant mice showed the observed low bone mass is not due to age-related bone loss. Mutations in LGR4 have been associated with family lineages with medical histories of rare bone disorders. Wild-type mice lacking LGR4 also displayed delayed osteoblast differentiation during development, showcasing the important role of LGR4 in bone mass regulation and development.
It chose to follow a single character to aid the immersion, creating the isolation of a vampire unable to trust any other character. This aided the story and compensated for the technical issues of allowing multiple player characters. Choice is a significant aspect of the game, requiring a non-linear design to accommodate the customized characters. Level design began with a list of factors such as Disciplines, stealth, and feats. Each area had to be viable for a shooting character (sufficient ammunition), a discipline-focused character (sufficient blood sources to keep the powers fueled), and a melee specialist (to reach enemies without being killed), with stealth options and option combinations. Level design began with a focus on stealth, considering the positioning of guards and the character's potential stealth capability at that point in the game. Then direct, combat-heavy, and dialogue paths were added. The amusement arcade area was to feature playable versions of Activision arcade games such as Pitfall!, though the idea was abandoned due to time constraints. Director Leonard Boyarsky considered the animation system important in the team's choice of the Source engine. The integrated "faceposer" tool allowed Troika to customize facial animations, expressions, gestures, and lip-synching, eliminating the need to explain what a character was doing. Every non-player character required a voiceover, which helped Troika define its characters more quickly.
Sources: en.wikipedia.org
By the end of August 1944 the German forces in Italy had formed the Gothic Line along the Apennine Mountains, and the 6th Division had come under the command of the US Fifth Army. The difficulty of using tanks in the mountains led to the Rhodesians of Prince Alfred's Guard temporarily adopting an infantry role, using dismounted tank machine-guns to support the Natal Carabineers during the fighting for Pistoia during early September. The Southern Rhodesian Anti-Tank Battery meanwhile converted partially from guns to 4.2-inch mortars. The South Africans and Rhodesians met with fierce resistance from the 16th SS Panzer Grenadier Division, but helped push the Germans northwards towards the Reno river. Hoping to repel Allied advances towards Bologna, the Germans took up positions on Monte Stanco overlooking the main roads towards the city. Two Allied assaults on the mountain—one by an Indian battalion, the other by the Royal Natal Carabineers—were repulsed. A third, larger attack at dawn on 13 October provided the Rhodesian Company of the Cape Town Highlanders with some of the fiercest combat they encountered in Italy. Advancing up the slope on the Allied right flank while being fired on from two directions, they suffered heavy casualties but achieved their objective and held it. Both Rhodesian artillery batteries provided support during the assault. When the line stabilised in November 1944, the portion occupied by the 6th Armoured Division extended for 16 kilometres (9.9 mi) along the heights over the Reno River.
People who have been fat since childhood generally have an inflated number of fat cells. People who become fat as adults may have no more fat cells than their lean peers, but their fat cells are larger. In general, people with an excess of fat cells find it harder to lose weight and keep it off than the obese who simply have enlarged fat cells.
A countercurrent multiplication loop is a system where fluid flows in a loop so that the entrance and exit are at similar low concentration of a dissolved substance but at the far end of the loop there is a high concentration of that substance. A buffer liquid between the incoming and outgoing tubes receives the concentrated substance. The incoming and outgoing tubes do not touch each other. The system allows the buildup of a high concentration gradually, by allowing a natural buildup of concentration towards the tip inside the in-going tube, (for example using osmosis of water out of the input pipe and into the buffer fluid), and the use of many active transport pumps each pumping only against a very small gradient, during the exit from the loop, returning the concentration inside the output pipe to its original concentration. The incoming flow starting at a low concentration has a semipermeable membrane with water passing to the buffer liquid via osmosis at a small gradient. There is a gradual buildup of concentration inside the loop until the loop tip where it reaches its maximum. Theoretically a similar system could exist or be constructed for heat exchange. In the example shown in the image, water enters at 299 mg/L (NaCl / H2O). Water passes because of a small osmotic pressure to the buffer liquid in this example at 300 mg/L (NaCl / H2O). Further up the loop there is a continued flow of water out of the tube and into the buffer, gradually raising the concentration of NaCl in the tube until it reaches 1199 mg/L at the tip.
Sources: en.wikipedia.org
Canada's economic integration with the United States has increased significantly since the Second World War. The Canada – United States Free Trade Agreement (FTA) of 1988 eliminated tariffs between the two countries, while the North American Free Trade Agreement (NAFTA) expanded the free-trade zone to include Mexico in 1994 (later replaced by the Canada–United States–Mexico Agreement). As of 2023, Canada is a signatory to 15 free trade agreements with 51 different countries. Canada is one of the few developed nations that are net exporters of energy. Atlantic Canada possess vast offshore deposits of natural gas, and Alberta hosts the fourth-largest oil reserves in the world. The vast Athabasca oil sands and other oil reserves give Canada 13 percent of global oil reserves, constituting the world's third- or fourth-largest. Canada is additionally one of the world's largest suppliers of agricultural products; the Canadian Prairies region is one of the most important global producers of wheat, canola, and other grains. Canada's main exports are zinc, uranium, gold, nickel, platinoids, aluminum, steel, iron ore, coking coal, lead, copper, molybdenum, cobalt, and cadmium. Canada has a sizeable manufacturing sector centred in southern Ontario and Quebec, with automobiles and aeronautics representing particularly important industries. The country's fishing and tourism industries are also a key contributor to the economy.
Sympathomimetics (catecholaminergics)—e.g. amphetamine, methamphetamine, cocaine, methylphenidate, ephedrine, pseudoephedrine Entactogens (serotonergics, primarily phenethylamines)—e.g. MDMA (which is also an amphetamine) Eugeroics, e.g. modafinil Others arecoline (found in Areca catechu) caffeine (found in Coffea spp.) nicotine (found in Nicotiana spp.) rauwolscine (found in Rauvolfia serpentina) yohimbine (Procomil; a tryptamine alkaloid found in Pausinystalia johimbe)
==== X-Ray Absorption Spectroscopy ==== X-Ray absorption spectroscopy (XAS) has been demonstrated as a technique for nuclear forensic investigations involving uranium speciation. Both the lower energy near-edge (XANES) and higher energy fine structure (EXAFS) analytical methods may be useful for this type of characterisation. Typically, XANES is employed to determine the oxidation state of the absorbing uranium atom, while EXAFS can be used to determine its local atomic environment. This spectroscopic method, when coupled with X-Ray diffraction (XRD), would be of most benefit to complex nuclear forensic investigations involving species of different oxidation states.
Sources: en.wikipedia.org
It varies slowly and reflects cumulative axis activity rather than momentary secretion. Growth hormone is released in pulses affected by sleep, stress, and meals, making single readings hard to interpret. The slower marker gives a more stable picture across a study period.
Assay calibration and antibody specificity differ between platforms, so identical samples can yield different numbers. A method change within one laboratory can shift results without any biological change. Cross-validation is often needed for multi-site work.
They capture only one moment in a pulsatile pattern and are strongly influenced by recent activity and meals. Repeated sampling or overnight profiles provide a more representative view. Provocative testing is an alternative when a dynamic response is of interest.
It mirrors the 44-residue form of human growth hormone-releasing hormone. A hexenoyl group on the N-terminal tyrosine distinguishes it from the unmodified hormone. The change is intended to improve resistance to enzymatic breakdown.